Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 5/20 | 0.36 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29229344 | 0.80 | MEN1 (0.38) | DYRK1AKDM4EKMT2AMEN1MAPT | |
| SCHEMBL7008476 | 0.80 | HTT (0.39) | HTTDYRK1ACYP1A2CYP2C19KDM4E | |
| SCHEMBL1932180 | 0.77 | HTT (0.41) | HTTDYRK1ACYP1A2CYP2C19KMT2A | |
| SCHEMBL1932691 | 0.77 | HTT (0.36) | HTTDYRK1ACYP1A2CYP2C19KDM4E | |
| SCHEMBL2698318 | 0.77 | HSP90AA1 (0.34) | HTTKDM4EMAPTSMN1; SMN2TP53 | |
| SCHEMBL13313448 | 0.77 | KDM4E (0.53) | HTTCYP1A2KDM4EKMT2AMEN1 | |
| SCHEMBL15272132 | 0.77 | KDM4E (0.34) | KDM4EKMT2AMEN1MAPTTDP1 | |
| SCHEMBL16039310 | 0.74 | NSD1 (0.39) | HTTCYP1A2CYP2C19KDM4EKMT2A | |
| SCHEMBL24253016 | 0.73 | DYRK1A (0.36) | HTTDYRK1AKMT2AMEN1MAPT | |
| SCHEMBL30467712 | 0.73 | DYRK1A (0.36) | HTTDYRK1AKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12150937-B2 | NLRP3 modulators | INNATE TUMOR IMMUNITY, INC. (US) | 2024-11-26 | — | — | US | disclosed |
| EP-3911417-B1 | HETEROCYCLIC NLRP3 MODULATORS , FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY INC (US) | 2022-10-26 | — | — | EP | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| US-20220087991-A1 | NLRP3 MODULATORS | INNATE TUMOR IMMUNITY INC (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3911417-A1 | HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | Innate Tumor Immunity, Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-113301962-A | Heterocyclic NLRP3 modulators for the treatment of cancer | 先天肿瘤免疫公司 | 2021-08-24 | — | — | CN | disclosed |
| WO-2020150114-A1 | HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150114-A1 | HETEROCYCLIC NLRP3 MODULATORS, FOR USE IN THE TREATMENT OF CANCER | INNATE TUMOR IMMUNITY, INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY | 2018-08-09 | — | — | US | disclosed |
| US-9938275-B2 | Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2018-04-10 | — | — | US | disclosed |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-03-22 | — | — | US | disclosed |
| WO-2006091647-A2 | METHOD OF PREFERENTIALLY INDUCING THE BIOSYNTHESIS OF INTERFERON | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091568-A2 | HYDROXYALKYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-31 | — | — | WO | disclosed |
| EP-1653914-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| EP-1653955-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M Innovative Properties Company (US) | 2006-05-10 | — | — | EP | disclosed |
| WO-2006038923-A2 | ARYL SUBSTITUTED IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-04-13 | — | — | WO | disclosed |
| WO-2006028545-A2 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-03-16 | — | — | WO | disclosed |
| WO-2005123080-A2 | NITROGEN-CONTAINING HETEROCYCLYL SUBSTITUTED IMIDAZOQUINOLINES AND IMIDAZONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005018551-A2 | OXIME SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
| WO-2005018556-A2 | HYDROXYLAMINE SUBSTITUTED IMIDAZO-CONTAINING COMPOUNDS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222906-A1 | SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES | IL2, IFNG, IL4 | HTT 3601/4885DYRK1A 4339/4885CYP1A2 1619/4885 |
| US-20220087991-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, PYCARD | HTT 2959/4885DYRK1A 4867/4885CYP1A2 558/4885 |
| US-20070066639-A1 | Oxime substituted imidazoquinolines | IFNG, IRF3, IL2 | HTT 4792/4885DYRK1A 3121/4885CYP1A2 303/4885 |
| US-12150937-B2 | NLRP3 modulators | NLRP3, NLRP1, PYCARD | HTT 2959/4885DYRK1A 4867/4885CYP1A2 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.